GlassScriptPhysician profile
Meredeth Mchugh Jackson
NPI 1245018217
$1,585.56
in general payments reported to CMS, 2019-2025
14 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $237 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.62 |
| Education | $149.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $243.12 | 2024-2025 | Cresemba |
| Glaxosmithkline, LLC. | $221.48 | 2024-2025 | Ojjaara |
| Sobi, INC | $159.62 | 2025 | |
| Celgene Corporation | $150.94 | 2025 | Reblozyl |
| Daiichi Sankyo INC. | $130.83 | 2025 | Vanflyta, Injectafer |
| Rigel Pharmaceuticals, INC. | $123.65 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Astrazeneca Pharmaceuticals LP | $121.87 | 2025 | |
| Genzyme Corporation | $108.11 | 2025 | |
| Novartis Pharmaceuticals Corporation | $100.69 | 2025 | |
| Stemline Therapeutics INC. | $98.26 | 2024-2025 | Elzonris |
| Blueprint Medicines Corporation | $56.64 | 2025 | Ayvakit |
| Genentech USA, INC. | $25.55 | 2025 | Venclexta |
| Geron Corporation | $24.77 | 2025 | Rytelo |
| Incyte Corporation | $20.03 | 2025 | Niktimvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredeth Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.